1. Insco, Megan L, Abraham, Brian J, Dubbury, Sara J, Boutz, Paul L, Zon, Leonard I. 2023. Oncogenic CDK13 mutations impede nuclear RNA surveillance. In Science (New York, N.Y.), 380, eabn7625. doi:10.1126/science.abn7625. https://pubmed.ncbi.nlm.nih.gov/37079685/
2. Quereda, Victor, Bayle, Simon, Vena, Francesca, Roush, William R, Duckett, Derek R. 2019. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. In Cancer cell, 36, 545-558.e7. doi:10.1016/j.ccell.2019.09.004. https://pubmed.ncbi.nlm.nih.gov/31668947/
3. Turner, Tychele N, Wilfert, Amy B, Bakken, Trygve E, Retterer, Kyle, Eichler, Evan E. 2019. Sex-Based Analysis of De Novo Variants in Neurodevelopmental Disorders. In American journal of human genetics, 105, 1274-1285. doi:10.1016/j.ajhg.2019.11.003. https://pubmed.ncbi.nlm.nih.gov/31785789/
4. Zhang, Yong, Chen, Xiao-Nan, Zhang, Hong, Qu, Chang-Bao, Yang, Zhan. 2023. CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. In Cell death and differentiation, 30, 2462-2476. doi:10.1038/s41418-023-01223-z. https://pubmed.ncbi.nlm.nih.gov/37845385/
5. . 2017. Prevalence and architecture of de novo mutations in developmental disorders. In Nature, 542, 433-438. doi:10.1038/nature21062. https://pubmed.ncbi.nlm.nih.gov/28135719/
6. Jiang, Baishan, Gao, Yang, Che, Jianwei, Zhang, Tinghu, Gray, Nathanael S. 2021. Discovery and resistance mechanism of a selective CDK12 degrader. In Nature chemical biology, 17, 675-683. doi:10.1038/s41589-021-00765-y. https://pubmed.ncbi.nlm.nih.gov/33753926/
7. Greenleaf, Arno L. 2018. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. In Transcription, 10, 91-110. doi:10.1080/21541264.2018.1535211. https://pubmed.ncbi.nlm.nih.gov/30319007/
智鼠故事 
